Cancer | Study, publication year | Country | No. of subjects; Type of study | RR (95% CI) | Notes | Measure/Range of vitamin D |
---|---|---|---|---|---|---|
Breast | Bauer SR et al., 2013 | USA | 11,656; 9 prospective | 0.99 (0.97-1.04) | Pre-menopausal | 17-33.1 ng/mL (Mean) |
Bauer SR et al., 2013 | USA | 11,656; 9 prospective | 0.97 (0.93-1.00) | Post-menopausal | 17-33.1 ng/mL (Mean) | |
Yin L et al., 2010 | Germany | Case-control | 0.74 (0.69-0.80) | Â | By 20 ng/mL increase | |
Chen P et al., 2010 | China | 11,330; 4 case-control/3 nested case-control | 0.55 (0.38-0.80) | Â | Top vs. bottom quantiles (varies) | |
Gandini S et al., 2011 | France | 10 studies | 0.89 (0.81-0.98) | Â | By 10 ng/mL increase | |
Chen P et al., 2013 | China | 26,317; 21 studies | 0.52 (0.40-0.68) | Â | By 1 ng/mL increase | |
Kidney | Gallicchio L et al., 2010 | USA | 1,550; 8 cohorts | 1.12 (0.79-1.59) | Low <37.5 nmol/L | <37.5 vs. 50-<75 (ref) nmol/L |
Gallicchio L et al., 2010 | USA | 1,550; 8 cohorts | 1.01 (0.65-1.58) | High ≥75 nmol/L | ≥75 vs. 50-<75 (ref) nmol/L | |
Pancreatic | Stolzenberg-Solomon RZ et al., 2010 | USA | 2,285; 8 cohorts | 0.96 (0.66-1.40) | Low <25 nmol/L | <25 vs. 50-<75 (ref) nmol/L |
Stolzenberg-Solomon RZ et al., 2010 | USA | 2,285; 8 cohorts | 2.14 (0.93-4.92) | High ≥100 nmol/L | ≥100 vs. 50-<75 (ref) nmol/L | |
Colorectal | Touvier M et al., 2011 | UK | 6 studies | 0.96 (0.94-0.97) | Â | 200-1,800 IU/L |
Lee JE et al., 2011 | USA | 8 prospective | 0.66 (0.54-0.81) | Â | Top vs. bottom quantiles (varies) | |
Ma Y et al., 2011 | China | 6,715; 9 studies | 0.67 (0.54-0.80) | Â | Top vs. bottom categories (varies) | |
Yin L et al., 2009 (Aliment Pharmacol Ther) | Germany | 3,556; 8 studies | 0.57 (0.43-0.76) | Â | By 20 ng/mL increase | |
Gorham ED et al., 2007 | USA | 1,448; 5 nested case–control | 0.49 (0.35-0.68) |  | Top vs. bottom quintile (varies) | |
Gandini S et al., 2011 | France | 9 studies | 0.85 (0.79-0.91) | Â | By 10 ng/mL increase | |
Prostate | Gilbert R et al., 2011 | UK | 14 cohort/nested case–control | 1.04 (0.99-1.10) |  | By 10 ng/mL increase |
Yin L et al., 2009 (Cancer Epidemiol) | Germany | 7,806; 11 studies | 1.03 (0.96-1.11) | Â | By 10 ng/mL increase | |
Gandini S et al., 2011 | France | 11 studies | 0.99 (0.95-1.03) | Â | By 10 ng/mL increase | |
Ovarian | Yin L et al., 2011 | Germany | 2,488; 10 longitudinal | 0.83 (0.63-1.08) | Â | By 20 ng/mL increase |
All Cancers | Yin L et al., 2013 | Germany | 5 studies | 0.89 (0.81-0.97) | Total cancer incidence | Per 50nmol/L increase |
13 studies | 0.83 (0.71-0.96) | Total cancer mortality | Per 50nmol/L increase | |||
3 studies | 0.76 (0.60-0.98) | Total cancer mortality (women) | Per 50nmol/L increase | |||
5 studies | 0.92 (0.65-1.32) | Total cancer mortality (men) | Per 50nmol/L increase |